Heart Failure : The Promise and Practice of Dopaminergic Agonists. . Updated Selection of Papers from a Satellite Symposium of the European Society of Cardiology, Vienna, 1988. Supplement Issue: Ameri

Ibopamine is an innovative, orally-active dopaminergic agonist.

It carries the promise of being amongst the most valuable of recent additions to the drugs currently available for the treatment of chronic heart failure.

The major objective of the reviews in this text is to examine how far it is possible to achieve the vital therapeutic targets with a single molecule of ibopamine through its active metabolite epinine.

These investigations suggest that ibopamine reduces the symptoms of heart failure, reduces diuretic requirements and improves exercise tolerance.

Cardiologists, gerontologists, investigators in drug studies, microcirculation and pharmacokinetics and others working with heart failure patients should find this book a useful reference.